Bausch Health Companies Inc. (NYSE:BHC) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET
Company Participants
Joe Papa - Chairman and Chief Executive Officer
Thomas Appio - Chief Executive Officer, Bausch Health
Tom Vadaketh - Chief Financial Officer, Bausch Health
Conference Call Participants
Ken Cacciatore - Cowen & Company
Chris Schott - JPMorgan
Doug Miehm - RBC Capital Markets
Greg Fraser - Truist Securities
Gary Nachman - BMO Capital Markets
Operator
Good day, and welcome to the Bausch Health First Quarter 2022 Earnings Conference Call. All participants will be in listen only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask question. [Operator Instructions] Please note today’s event is being recorded.
I would now like to turn the conference over to Christina Chang [ph], Senior Vice President, Investor Relations. Please go ahead, ma'am.
Unidentified Company Representative
Good morning. Welcome everyone to our first quarter 2022 earnings conference call. Participating in today’s call are the Chairman of Bausch Health and Bausch + Lomb’s CEO, Mr. Joe Papa; new CEO of Bausch Health, Mr. Thomas Appio; and the new Chief Financial Officer of Bausch Health, Mr. Tom Vadaketh.
Before we begin, I'd like to remind you that our presentation today contains forward-looking information. Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward-looking statements.
Please refer to our SEC filings and filings with the Canadian Securities Administrator for a list of factors that could cause our actual results to differ materially from our expectations. We use non-GAAP financial measures to help investors understand our ongoing business performance.
Non-GAAP financial measures may not be comparable to similarly titled measures used by other companies and should not be considered along with, but not as alternative to, operating performance measures as prescribed by the GAAP. You will find reconciliations to our non-GAAP measures in our appendix of the presentation online. Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance.
I would like to take a moment to remind you that the first quarter results are the fully consolidated results of Bausch Health, covering the quarter ended March 31st, before the IPO of Bausch + Lomb, which is scheduled to close this morning, subject to customary closing conditions.
Our discussion today will focus on Bausch Pharma and Solta and we will briefly comment on Bausch + Lomb's results disclosed in its IPO prospectus. Bausch + Lomb will file a separate 10-Q within 45 days after IPO pricing and will host a separate earnings call in conjunction with the filing. Please note that the results of the B&L segment presented here today will differ from the results presented in the stand-alone financial statements of Bausch + Lomb as those stand-alone state results include certain corporate and shared costs that are allocated to Bausch & Lomb, which are not included in our B&L segment results.